| Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs A Majowicz, B Nijmeijer, MH Lampen, L Spronck, M de Haan, H Petry, ... Molecular therapy Methods & clinical development 14, 27-36, 2019 | 101 | 2019 |
| Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1 A Majowicz, D Salas, N Zabaleta, E Rodríguez-Garcia, ... Molecular Therapy 25 (8), 1831-1842, 2017 | 82 | 2017 |
| Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery A Majowicz, P Maczuga, KL Kwikkers, S van der Marel, R van Logtenstein, ... The journal of gene medicine 15 (6-7), 219-232, 2013 | 57 | 2013 |
| Gene and cell therapy based treatment strategies for inflammatory bowel diseases S van der Marel, A Majowicz, S van Deventer, H Petry, DW Hommes, ... World Journal of Gastrointestinal Pathophysiology 2 (6), 114, 2011 | 37 | 2011 |
| Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis S Van Der Marel, A Majowicz, K Kwikkers, R van Logtenstein, AA te Velde, ... World Journal of Gastroenterology: WJG 18 (32), 4288, 2012 | 34 | 2012 |
| Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood CJ Smith, N Ross, A Kamal, KY Kim, E Kropf, P Deschatelets, C Francois, ... Frontiers in Immunology 13, 999021, 2022 | 24 | 2022 |
| Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo A Majowicz, S van der Marel, AA te Velde, SL Meijer, H Petry, ... BMC gastroenterology 12, 1-9, 2012 | 22 | 2012 |
| Therapeutic factor IX (FIX) activity after single treatment with AMT-060 (AAV5-FIX) in hemophilia B patients with pre-existing anti-AAV5 humoral immunity A Majowicz, B Nijmeijer, MH Lampen, L Spronck, H Petry, C Meyer, ... American Society of Gene & Cell Therapy (ASGCT) 21st annual meeting, 16-19, 2018 | 5 | 2018 |
| Seroprevalence of pre-existing nabs against AAV1, 2, 5, 6 and 8 in South African hemophilia B patient population A Majowicz, N Ncete, F van Waes, N Timmer, SJ van Deventer, ... Blood 134, 3353, 2019 | 4 | 2019 |
| Therapeutic human Factor IX (hFIX) activity after single treatment with AMT-060 (AAV5-hFIX) or AMT-061 (AAV5-Padua hFIX) in Hemophilia B patients with pre-existing anti-AAV5 … A Majowicz, B Nijmeijer, M Lampen, R Gut, E Sawyer, L Spronck, ... Haemophilia 26, 20-20, 2020 | 3 | 2020 |
| Prevalence and affinity/avidity assessment of pre-existing NABS against AAV1, 2, 5 and 8 analyzed in the serum of 300 healthy donors A Majowicz, F van Waes, N Timmer, SJ van Deventer, V Ferreira HAEMOPHILIA 26, 53-53, 2020 | 3 | 2020 |
| Effects of complement component 1 (C1) inhibition on AAV-based gene transfer efficacy and immunogenicity in mice N Ross, C Smith, A Kamal, A Majowicz, F Mingozzi, K Kuranda MOLECULAR THERAPY 30 (4), 559-560, 2022 | 2 | 2022 |
| Efficacy of Immunomodulatory Regimens to Prevent Anti-AAV Humoral Response and to Enable AAV Re-administration in Mouse Gene Transfer Model A Majowicz, E Kropf, A Kamal, J Rasouli, F Mingozzi, K Kuranda MOLECULAR THERAPY 30 (4), 337-337, 2022 | 1 | 2022 |
| Presence of Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5 Neutralizing Antibodies (NABs) in Serum of Huntington Disease (HD) Patients Was Not Associated with … A Majowicz, F van Waes, A Valles, S van Deventer, M Gilling, A Ehrhardt, ... MOLECULAR THERAPY 29 (4), 357-357, 2021 | 1 | 2021 |
| SEROPREVALENCE OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, 6 AND 8 IN SOUTH AFRICAN HEMOPHILIA B PATIENT POPULATION JN Mahlangu, A Majowicz, N Ncete, F van Waes, N Timmer, ... Haemophilia 26, 88-88, 2020 | 1 | 2020 |
| Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5 Neutralizing Antibodies (NABs) Titers in Minipig Serum Do Not Reflect Levels of Anti-AAV5 NABs Titers in Their … A Majowicz, A Valles, F van Waes, B Bohuslavova, Z Ellederova, J Motlik, ... MOLECULAR THERAPY 27 (4), 140-140, 2019 | 1 | 2019 |
| Successful repeated hepatic gene delivery in non-human primates achieved with AAV5 by use of immune adsorption D Salas, K Kwikker, A Majowicz, N Zabeleta, H Petry, GG Aseguinolaza, ... American Society of Gene and Cell Therapy 20th annual meeting, Washington, DC, 2017 | 1 | 2017 |
| Circulating Anti-AAV5 Neutralizing Antibody Titers up to 1: 1031 Do Not Affect Liver Transduction Efficacy of AAV5 Vectors in Non-Human Primates A Majowicz, L Spronck, M de Haan, H Petry, B Nijmeijer, V Ferreira Mol. Ther 25, 94, 2017 | 1 | 2017 |
| Complement System Response to Adeno-Associated Virus Vector Gene Therapy E Kropf, DM Markusic, A Majowicz, F Mingozzi, K Kuranda Human Gene Therapy, 2024 | | 2024 |
| Characterization of the Innate Immune Response to AAV in Human Blood and the Central Role of Complement CJ Smith, N Ross, A Kamal, P Deschatelets, WJ Quinn, A Majowicz, ... MOLECULAR THERAPY 30 (4), 20-20, 2022 | | 2022 |
